Johnson & Johnson NYSE: JNJ has filed 13-F forms with the SEC as an investor. Johnson & Johnson is itself a publicly traded company. Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. For more information on Johnson & Johnson stock, visit the Johnson & Johnson stock profile here.
Investment Activity
- Johnson & Johnson has $427.33 million in total holdings as of December 31, 2022.
- Johnson & Johnson owns shares of 20 different stocks, but just 8 companies or ETFs make up 80% of its holdings.
- Approximately 0.02% of the portfolio was purchased this quarter.
- About 0.65% of the portfolio was sold this quarter.
- This quarter, Johnson & Johnson has purchased 20 new stocks and bought additional shares in 0 stocks.
- Johnson & Johnson sold shares of 1 stock and completely divested from 1 stock this quarter.
Largest Holdings
- Rapport Therapeutics, Inc.
- $51,160,084
- Contineum Therapeutics Inc.
- $37,881,371
Largest New Holdings this Quarter
Largest Purchases this Quarter
Largest Sales this Quarter
- BiomX
- 1,730,880 shares (about $1.77M)
